Albert forms collaborations to access existing research experts, clinical infrastructure and patient pools to deliver its psychedelic-assisted therapies. Less capital intensive lower risk.
Albert Labs addresses niche mental health indications that have urgent and unmet needs across the UK and Europe (i.e. cancer-related anxiety) to avoid competing with big pharma.
Albert Labs uses an accelerated pathway known as Real-World Evidence (RWE) study to quickly deliver approved therapies and move into revenue generation.
Fill out this form and we will email you to start the conversation.
Albert Labs is the first psychedelics company to leverage RWE studies that will reduce the time and expense necessary to deliver its therapies to patients with urgent unmet needs.
Albert Labs owns the study data to develop and protect its recognized psilocybin-based therapies through the formulation and delivery of natural psilocybin.
Albert will start in the UK with the top 10 hospital centers and then scale its collaborative model across Europe - 1.2 million patients in the UK suffering from cancer-related anxiety.
Fill out this form and we will email you with further instruction.
*Upon completing this form one of the Albert Labs team will ensure you qualify for the investment.
Your browser does not support iframes, click here!
Request a call-back from one of the Albert Labs’ Team.